[go: up one dir, main page]

TWI349672B - Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors - Google Patents

Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors

Info

Publication number
TWI349672B
TWI349672B TW093112449A TW93112449A TWI349672B TW I349672 B TWI349672 B TW I349672B TW 093112449 A TW093112449 A TW 093112449A TW 93112449 A TW93112449 A TW 93112449A TW I349672 B TWI349672 B TW I349672B
Authority
TW
Taiwan
Prior art keywords
pyrazolo
preparation
kinase inhibitors
quinazoline derivatives
quinazoline
Prior art date
Application number
TW093112449A
Other languages
English (en)
Other versions
TW200505924A (en
Inventor
Traquandi Gabriella
Gabriella Brasca Maria
D Alessio Roberto
Polucci Paolo
Roletto Fulvia
Vulpetti Anna
Pevarello Paolo
Panzeri Achille
Quartieri Francesca
Ferguson Ron
Vianello Paola
Fancelli Daniele
Original Assignee
Nerviano Medical Sciences Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33476970&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI349672(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nerviano Medical Sciences Srl filed Critical Nerviano Medical Sciences Srl
Publication of TW200505924A publication Critical patent/TW200505924A/zh
Application granted granted Critical
Publication of TWI349672B publication Critical patent/TWI349672B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW093112449A 2003-05-22 2004-05-04 Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors TWI349672B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47266103P 2003-05-22 2003-05-22

Publications (2)

Publication Number Publication Date
TW200505924A TW200505924A (en) 2005-02-16
TWI349672B true TWI349672B (en) 2011-10-01

Family

ID=33476970

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093112449A TWI349672B (en) 2003-05-22 2004-05-04 Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors

Country Status (36)

Country Link
US (9) US7482354B2 (zh)
EP (1) EP1636236B1 (zh)
JP (1) JP5043432B2 (zh)
KR (1) KR101084871B1 (zh)
CN (2) CN1826343A (zh)
AP (1) AP2064A (zh)
AR (2) AR044543A1 (zh)
AU (1) AU2004240772B2 (zh)
BR (2) BRPI0410563B8 (zh)
CA (1) CA2526578C (zh)
CO (1) CO5721006A2 (zh)
CR (1) CR8102A (zh)
CY (1) CY1114708T1 (zh)
DK (1) DK1636236T3 (zh)
EA (1) EA010904B1 (zh)
EC (1) ECSP056194A (zh)
ES (1) ES2436524T3 (zh)
GE (1) GEP20094664B (zh)
HR (1) HRP20050967B8 (zh)
IL (1) IL172046A (zh)
IS (1) IS2939B (zh)
ME (1) ME00142B (zh)
MX (1) MXPA05012573A (zh)
MY (1) MY142019A (zh)
NO (1) NO334992B1 (zh)
NZ (1) NZ543661A (zh)
OA (1) OA13170A (zh)
PL (1) PL1636236T3 (zh)
PT (1) PT1636236E (zh)
RS (2) RS52899B (zh)
SI (1) SI1636236T1 (zh)
TN (1) TNSN05298A1 (zh)
TW (1) TWI349672B (zh)
UA (1) UA80763C2 (zh)
WO (1) WO2004104007A1 (zh)
ZA (1) ZA200509486B (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI855088B (zh) * 2019-06-06 2024-09-11 美商阿克思生物科學有限公司 製備胺基嘧啶化合物的方法

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004240772B2 (en) * 2003-05-22 2011-04-28 Nerviano Medical Sciences S.R.L. Pyrazolo-quinazoline derivatives,process for their preparation and their use as kinase inhibitors
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
EP1694686A1 (en) 2003-12-19 2006-08-30 Takeda San Diego, Inc. Kinase inhibitors
US7772232B2 (en) 2004-04-15 2010-08-10 Bristol-Myers Squibb Company Quinazolinyl compounds as inhibitors of potassium channel function
ITMI20041033A1 (it) * 2004-05-24 2004-08-24 Neuroscienze S C A R L Composti farmaceutici
EP1778669A2 (en) 2004-08-18 2007-05-02 Takeda San Diego, Inc. Kinase inhibitors
DE602005023333D1 (de) 2004-10-15 2010-10-14 Takeda Pharmaceutical Kinaseinhibitoren
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
CA2623729A1 (en) 2006-02-10 2007-08-16 Nerviano Medical Sciences S.R.L. Combinations comprising a cdk inhibitor and a growth factor antibody or anti-mitotic
EP2026800A1 (en) * 2006-05-09 2009-02-25 Novartis AG Combination comprising an iron chelator and an anti-neoplastic agent and use thereof
WO2007149395A2 (en) * 2006-06-20 2007-12-27 Amphora Discovery Corporation 2,5-substituted oxazole derivatives as protein kinase inhibitors for the treatment of cancer
US7517882B2 (en) * 2006-09-18 2009-04-14 Polaris Group Protein kinase inhibitors
EA200970361A1 (ru) 2006-10-09 2010-02-26 Такеда Фармасьютикал Компани Лимитед Ингибиторы киназы
ZA200904912B (en) * 2006-12-21 2010-09-29 Nerviano Medical Sciences Srl Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
PL2125822T3 (pl) * 2006-12-21 2015-04-30 Nerviano Medical Sciences Srl Podstawione pochodne pirazolochinazoliny, sposób ich wytwarzania oraz ich zastosowanie jako inhibitory kinaz
EP2213673B1 (en) 2007-10-23 2013-06-05 Msd K.K. Pyridone-substituted-dihydropyrazolopyrimidinone derivative
BRPI0821209A2 (pt) * 2007-12-19 2019-09-24 Amgen Inc composto, composição farmacêutica, métodos de tratar câncer, para reduzir o tamanho de tumor, para tratar distúrbios, e para reduzir metástase em um tumor.
ATE531372T1 (de) * 2008-04-07 2011-11-15 Amgen Inc Gem-disubstituierte und spirocyclische aminopyridine/pyrimidine als zellcyclus- inhibitoren
TWI426074B (zh) * 2008-04-30 2014-02-11 Nerviano Medical Sciences Srl ５－（２－胺基－嘧啶－４－基）－２－芳基－１ｈ－吡咯－３－羧醯胺之製造方法
SI2303891T1 (sl) * 2008-06-26 2016-06-30 Les Laboratoires Servier Pirazolo kinazolini kot modulatorji aktivnosti protein kinaze
WO2010012777A1 (en) * 2008-07-29 2010-02-04 Nerviano Medical Sciences S.R.L. THERAPEUTIC COMBINATION COMPRISING A CDKs INHIBITOR AND AN ANTINEOPLASTIC AGENT
ES2532732T3 (es) * 2008-07-29 2015-03-31 Nerviano Medical Sciences S.R.L. Uso de un inhibidor de CDK para el tratamiento del glioma
EP2350084B1 (en) * 2008-10-17 2015-06-24 Boehringer Ingelheim International GmbH Tetra-aza-heterocycles as phosphatidylinositol-3-kinases (pi3-kinases) inhibitor
CN102223885B (zh) * 2008-11-24 2013-04-03 内尔维阿诺医学科学有限公司 用于治疗间皮瘤的cdk抑制剂
IT1395724B1 (it) * 2009-02-25 2012-10-19 Neuroscienze Pharmaness S C A R L Composti farmaceutici
ES2445896T3 (es) * 2009-03-20 2014-03-05 Nerviano Medical Sciences S.R.L. Uso de un inhibidor de quinasa para el tratamiento del timoma
JP5901020B2 (ja) * 2009-04-22 2016-04-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌の治療用ＰＩ３−キナーゼ阻害薬としてのチア−トリアザ−ａｓ−インダセン
ES2660146T3 (es) 2009-04-29 2018-03-21 Nerviano Medical Sciences S.R.L. Sales del inhibidor de cdk
AR076784A1 (es) * 2009-05-26 2011-07-06 Nerviano Medical Sciences Srl Combinacion terapeutica que comprende un inhibidor de plk1 y un agente antineoplasico
JP5851990B2 (ja) * 2009-07-29 2016-02-03 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ Ｐｌｋ阻害剤の塩
RU2012136451A (ru) * 2010-01-28 2014-03-10 Президент Энд Феллоуз Оф Гарвард Колледж Композиции и способы улучшения активности протеасомы
US8735386B2 (en) 2010-07-23 2014-05-27 Boehringer Ingelheim International Gmbh Aminopyrazoloquinazolines
JP5997143B2 (ja) * 2010-07-30 2016-09-28 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ タンパク質キナーゼ活性の調整剤としてのイソオキサゾロ−キナゾリン
CN103124723A (zh) 2010-09-23 2013-05-29 先正达参股股份有限公司 新颖的杀微生物剂
PL2632467T3 (pl) * 2010-10-25 2016-12-30 Inhibitory CDK
CN103298816A (zh) * 2010-12-17 2013-09-11 内尔维阿诺医学科学有限公司 作为激酶抑制剂的取代的吡唑并-喹唑啉衍生物
US8916577B2 (en) * 2011-01-26 2014-12-23 Nerviano Medical Sciences S.R.L. Tricyclic derivatives, process for their preparation and their use as kinase inhibitors
BR112013018515B1 (pt) * 2011-01-26 2021-06-29 Nerviano Medical Sciences S.R.I Derivados de pirrol tricíclico, processo para sua preparação e seu uso como inibidores da quinase
WO2012117021A2 (en) 2011-03-03 2012-09-07 Syngenta Participations Ag Novel microbiocidal oxime ethers
MX2013010871A (es) 2011-03-23 2014-01-31 Amgen Inc Inhibidores dobles triciclicos fusionados de cdk 4/6 y flt3.
HRP20190867T1 (hr) 2011-05-12 2019-07-12 Proteostasis Therapeutics, Inc. Regulatori proteostaze
WO2013092460A1 (en) 2011-12-20 2013-06-27 Syngenta Participations Ag Cyclic bisoxime microbicides
AR089776A1 (es) 2012-01-23 2014-09-17 Boehringer Ingelheim Int 5,8-dihidro-6h-pirazolo[3,4-h]quinazolinas como inhibidores de igf-1r/ir
EP2641901A1 (en) 2012-03-22 2013-09-25 Syngenta Participations AG. Novel microbiocides
JP6326057B2 (ja) 2012-11-07 2018-05-16 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 置換ピリミジニルおよびピリジニル−ピロロピリジノン、これらの調製のための方法、およびキナーゼ阻害剤としてのこれらの使用
WO2014116228A1 (en) 2013-01-25 2014-07-31 President And Fellows Of Harvard College Usp14 inhibitors for treating or preventing viral infections
WO2014144740A2 (en) 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Highly active anti-neoplastic and anti-proliferative agents
WO2014144326A1 (en) 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Transient protection of normal cells during chemotherapy
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
RU2692479C2 (ru) 2014-04-07 2019-06-25 Недерлэндс Транслэшинал Рисерч Сентер Б.В. (5,6-дигидро)пиримидо[4,5-е]индолизины
WO2015161283A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic lactams for use in hspc-sparing treatments for rb-positive abnormal cellular proliferation
DK3148532T3 (en) 2014-05-28 2021-04-26 Piramal Entpr Ltd Pharmaceutical Combination Comprising a CDK Inhibitor and a Thioredoxin Reductase Inhibitor for the Treatment of Cancer
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
WO2016040858A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
CN108348486A (zh) 2015-07-17 2018-07-31 巴斯德研究院 用作卫星细胞自我更新和/或分化的启动子的5-羟色胺1b受体激动剂
BR112019000706A8 (pt) 2016-07-15 2022-12-06 Pasteur Institut Agente de estímulo do receptor 1b de 5-hidroxitriptamina para reparo de pele e/ou cabelo
DK3505519T3 (da) * 2016-11-11 2022-02-07 Yangtze River Pharm Group Co Pyridinamin-substituerede heterotricyclo-forbindelser, fremstilling deraf og anvendelse i medicin
CN110997678B (zh) * 2017-07-11 2023-02-21 内尔维亚诺医疗科学公司 作为胆碱激酶抑制剂的吡唑并喹唑啉衍生物
CN107383019B (zh) * 2017-07-28 2019-10-15 江苏艾凡生物医药有限公司 吡唑并[4,3-h]喹唑啉类化合物及其用途
WO2019029663A1 (zh) * 2017-08-11 2019-02-14 晟科药业（江苏）有限公司 1h-吡唑并[4,3-h]喹唑啉类化合物作为蛋白激酶抑制剂
US20220363690A1 (en) * 2019-09-05 2022-11-17 Chengdu Cynogen Bio-Pharmaceutical Technology Co., Ltd. Isoxazolo[5,4-h]quinazoline compounds as protein kinase inhibitors
WO2021084541A1 (en) * 2019-10-31 2021-05-06 Sol-Gel Technologies Ltd. Treatment of hair loss disorders with a topical egfr inhibitor
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
CN116547280A (zh) * 2020-10-08 2023-08-04 雷多纳治疗公司 用于治疗癌症的苯并[h]喹唑啉-4-胺和噻吩并[3,2-h]喹唑啉-4-胺衍生物
CN116601155A (zh) * 2020-11-26 2023-08-15 成都赛璟生物医药科技有限公司 杂芳基并喹唑啉类化合物作为蛋白激酶抑制剂
CN114685520B (zh) * 2020-12-25 2024-08-30 武汉誉祥医药科技有限公司 三并环化合物及其药物组合物和应用
WO2022143576A1 (zh) * 2020-12-31 2022-07-07 恒元生物医药科技(苏州)有限公司 一种吡唑并喹唑啉类化合物、其制备方法及应用
EP4289852A4 (en) * 2021-02-08 2025-02-26 NovaOnco JS Therapeutics Co., Ltd. 5,6-DIHYDROTHIENO[3,4-H]QUINAZOLINE COMPOUND
KR20240067229A (ko) * 2021-06-22 2024-05-16 택시스 파마슈티칼스, 인크. 치료학적 화합물
CN113527310B (zh) * 2021-07-30 2022-09-23 上海市肺科医院 用于减轻自身免疫性疾病患者不良炎性反应的小分子化合物及其应用
CN118382626A (zh) * 2021-12-10 2024-07-23 山东绿叶制药有限公司 蛋白激酶抑制剂及其制备方法和应用
EP4653443A1 (en) * 2023-01-17 2025-11-26 Phil Rivers Technology Co., Ltd Stereoisomer and deuterated derivative of pyrazoloquinazoline compound and use
WO2024251230A1 (zh) * 2023-06-08 2024-12-12 山东绿叶制药有限公司 一种plk1激酶抑制剂的盐型、晶型及其制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2119975A (en) * 1936-08-26 1938-06-07 Beatrice S Nazel Fluid pressure hammer
JP3907220B2 (ja) * 1994-06-30 2007-04-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 複素環含有化合物
DK0831829T3 (da) 1995-06-07 2003-12-15 Pfizer Heterocykliske, ringkondenserede pyrimidinderivater
AU5330698A (en) 1996-12-23 1998-07-17 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
GB9713087D0 (en) 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
GB9911053D0 (en) 1999-05-12 1999-07-14 Pharmacia & Upjohn Spa 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents
EE200200065A (et) 1999-08-12 2003-04-15 Pharmacia Italia S.P.A. 3-aminopürasooli derivaadid, nende valmistamine ja kasutamine vähivastaste toimeainetena ning neid sisaldav farmatseutiline kompositsioon
US6387900B1 (en) 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
IL153997A0 (en) 2000-08-10 2003-07-31 Pharmacia Italia Spa Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
DE60132702T2 (de) * 2000-08-11 2009-03-19 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield Heterozyklische verbindungen als inhibitoren von tyrosin-kinasen
JP2004517840A (ja) 2000-11-27 2004-06-17 フアルマシア・イタリア・エツセ・ピー・アー フェニルアセトアミド−ピラゾール誘導体およびそれの抗腫瘍薬としての使用
NZ527767A (en) 2001-01-26 2004-11-26 Pharmacia Italia S Chromane derivatives, process for their preparation and their use as antitumor agents
US20030100594A1 (en) * 2001-08-10 2003-05-29 Pharmacia Corporation Carbonic anhydrase inhibitor
JP2005501083A (ja) * 2001-08-10 2005-01-13 ファルマシア・コーポレーション 炭酸脱水酵素阻害剤
CN1556702A (zh) 2001-09-26 2004-12-22 具有作为激酶抑制剂的活性的氨基吲唑衍生物、它们的制备方法和含有它们的药物组合物
WO2003070706A1 (en) * 2002-02-19 2003-08-28 Pharmacia Corporation Tricyclic pyrazole derivatives for the treatment of inflammation
AU2004240772B2 (en) 2003-05-22 2011-04-28 Nerviano Medical Sciences S.R.L. Pyrazolo-quinazoline derivatives,process for their preparation and their use as kinase inhibitors
PL2125822T3 (pl) * 2006-12-21 2015-04-30 Nerviano Medical Sciences Srl Podstawione pochodne pirazolochinazoliny, sposób ich wytwarzania oraz ich zastosowanie jako inhibitory kinaz

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI855088B (zh) * 2019-06-06 2024-09-11 美商阿克思生物科學有限公司 製備胺基嘧啶化合物的方法

Also Published As

Publication number Publication date
ECSP056194A (es) 2006-04-19
RS20050944A (sr) 2008-06-05
RS52899B (sr) 2014-02-28
IS8132A (is) 2005-11-18
GEP20094664B (en) 2009-04-10
AP2064A (en) 2009-10-30
NO20055496D0 (no) 2005-11-21
BR122019010200B1 (pt) 2020-12-15
US8981089B2 (en) 2015-03-17
TNSN05298A1 (fr) 2007-07-10
US20210300935A1 (en) 2021-09-30
US20250011333A1 (en) 2025-01-09
US20070185143A1 (en) 2007-08-09
US8541429B2 (en) 2013-09-24
US20130338148A1 (en) 2013-12-19
CN1826343A (zh) 2006-08-30
PL1636236T3 (pl) 2014-02-28
HRP20050967B1 (hr) 2014-03-28
AU2004240772A1 (en) 2004-12-02
NO334992B1 (no) 2014-08-18
TW200505924A (en) 2005-02-16
BRPI0410563B8 (pt) 2021-05-25
JP5043432B2 (ja) 2012-10-10
CN102079746A (zh) 2011-06-01
BR122019010200B8 (pt) 2021-07-27
PT1636236E (pt) 2013-12-16
EP1636236A1 (en) 2006-03-22
BRPI0410563A (pt) 2006-06-20
MY142019A (en) 2010-08-16
AP2005003452A0 (en) 2005-12-31
AU2004240772B2 (en) 2011-04-28
US20150158876A1 (en) 2015-06-11
CA2526578A1 (en) 2004-12-02
OA13170A (en) 2006-12-13
MXPA05012573A (es) 2006-02-22
US20170050972A1 (en) 2017-02-23
ES2436524T3 (es) 2014-01-02
US20170190714A1 (en) 2017-07-06
ME00142B (me) 2010-10-10
WO2004104007A1 (en) 2004-12-02
KR101084871B1 (ko) 2011-11-21
ZA200509486B (en) 2008-09-25
CR8102A (es) 2006-08-09
HRP20050967B8 (hr) 2014-04-25
EA010904B1 (ru) 2008-12-30
US7482354B2 (en) 2009-01-27
NO20055496L (no) 2006-02-14
IS2939B (is) 2016-03-15
DK1636236T3 (da) 2013-12-09
US20190194214A1 (en) 2019-06-27
US9464090B2 (en) 2016-10-11
US10280176B2 (en) 2019-05-07
UA80763C2 (en) 2007-10-25
IL172046A (en) 2017-03-30
SI1636236T1 (sl) 2014-01-31
MEP25908A (bs) 2010-06-10
CO5721006A2 (es) 2007-01-31
US20090124605A1 (en) 2009-05-14
US9637497B2 (en) 2017-05-02
BRPI0410563B1 (pt) 2020-12-01
AR044543A1 (es) 2005-09-21
KR20060015294A (ko) 2006-02-16
CA2526578C (en) 2012-01-24
EP1636236B1 (en) 2013-10-09
JP2007502851A (ja) 2007-02-15
AR102722A2 (es) 2017-03-22
HRP20050967A2 (en) 2007-05-31
CY1114708T1 (el) 2016-10-05
EA200501849A1 (ru) 2006-06-30
NZ543661A (en) 2009-05-31

Similar Documents

Publication Publication Date Title
AP2064A (en) Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
AP2048A (en) Diazepinoindole derivatives as kinase inhibitors
IL173380A0 (en) Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors
IL173200A0 (en) Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors
IL165515A0 (en) Bisindolyl-maleimid derivatives as kinase inhibitors
IL172132A0 (en) Thienopyridone derivatives as kinase inhibitors
PL2125822T3 (pl) Podstawione pochodne pirazolochinazoliny, sposób ich wytwarzania oraz ich zastosowanie jako inhibitory kinaz
IL173381A0 (en) 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
ZA201202026B (en) PYROLO[2,3-b] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS
HUP0402245A3 (en) Pyrimidinyl-aminobenzamide derivatives as glycogen synthase kinase 3betha inhibitors, their use, pharmaceutical compositions containing them and process for producing them
AU2003271566A8 (en) Pyrrolopyrazines as kinase inhibitors
EP1689393A4 (en) PREPARATION OF 1,7-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS
IL182054A0 (en) Novel bis-azaindole derivatives, preparation and pharmaceutical use thereof as kinase inhibitors
EP1670466A4 (en) PREPARATION OF 1,6,7-TRISUBSTITUTED AZABENIC ZIMIDAZOLES AS KINASE-INHIBITORS
EP1590333A4 (en) GLYCOGENE SYNTHASE KINASE 3BETA INHIBITOR, COMPOSITION AND PROCESS FOR PREPARING THE SAME
IL179424A0 (en) Substituted oxazole -benzoisothiazole dioxide derivatives, process for their preparation and their use
IL179758A0 (en) Substituted tetrahydro - 2h - isoquinolin - 1 - one derivatives, method for the production thereof, and use of the same as medicaments
IL175300A0 (en) Indirubin-type compounds, compositions, and methods for their use
IL172375A0 (en) Chinazoline derivatives as aurora kinase inhibitors
PL377741A1 (pl) Pochodne diarylocykloalkilowe, sposób ich wytwarzania i ich zastosowanie jako środka leczniczego
PL378121A1 (pl) Sposób wytwarzania pirolotriazynowych inhibitorów kinazy
HUP0401522A2 (en) New 4-benzylidene-piperidine derivatives, pharmaceutical compositions containing the same and process for their preparation
ZA200904912B (en) Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
IL186062A0 (en) Indanyl-piperazine derivatives, method for preparing same and pharmaceutical compositions containing same
IL164248A0 (en) Acyl-3-carboxyphenylurea derivatives, processes for preparing them and their use

Legal Events

Date Code Title Description
MK4A Expiration of patent term of an invention patent